Sustained proliferation in cancer: Mechanisms and novel therapeutic targets MA Feitelson, A Arzumanyan, RJ Kulathinal, SW Blain, RF Holcombe, ... Seminars in cancer biology 35, S25-S54, 2015 | 805 | 2015 |
Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 312 | 2015 |
Emerging variants of castration-resistant prostate cancer PJ Vlachostergios, L Puca, H Beltran Current oncology reports 19, 1-10, 2017 | 202 | 2017 |
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD … ES Antonarakis, P Isaacsson Velho, W Fu, H Wang, N Agarwal, ... JCO precision oncology 4, 370-381, 2020 | 188 | 2020 |
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling BD Robinson, PJ Vlachostergios, B Bhinder, W Liu, K Li, TJ Moss, ... Nature communications 10 (1), 2977, 2019 | 176 | 2019 |
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells CD Befani, PJ Vlachostergios, E Hatzidaki, A Patrikidou, S Bonanou, ... Journal of molecular medicine 90, 45-54, 2012 | 159 | 2012 |
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis I Gioulbasanis, P Georgoulias, PJ Vlachostergios, V Baracos, S Ghosh, ... Lung cancer 74 (3), 516-520, 2011 | 113 | 2011 |
Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies L Puca, PJ Vlachostergios, H Beltran Cold Spring Harbor perspectives in medicine 9 (2), a030593, 2019 | 110 | 2019 |
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer I Gioulbasanis, A Pallis, PJ Vlachostergios, A Xyrafas, Z Giannousi, ... Lung Cancer 77 (2), 383-388, 2012 | 78 | 2012 |
Targeting neuroendocrine prostate cancer: molecular and clinical perspectives PJ Vlachostergios, CN Papandreou Frontiers in oncology 5, 6, 2015 | 76 | 2015 |
Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives A Dhaliwal, PJ Vlachostergios, KG Oikonomou, Y Moshenyat World journal of gastrointestinal oncology 7 (10), 178, 2015 | 64 | 2015 |
SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy V Conteduca, SY Ku, L Puca, M Slade, L Fernandez, J Hess, R Bareja, ... Molecular cancer therapeutics 19 (5), 1157-1164, 2020 | 62 | 2020 |
Elevated lactic acid is a negative prognostic factor in metastatic lung cancer PJ Vlachostergios, KG Oikonomou, E Gibilaro, G Apergis Cancer Biomarkers 15 (6), 725-734, 2015 | 62 | 2015 |
Treatment resistance in urothelial carcinoma: an evolutionary perspective PJ Vlachostergios, BM Faltas Nature reviews Clinical oncology 15 (8), 495-509, 2018 | 59 | 2018 |
Orbital metastasis of breast carcinoma PJ Vlachostergios, IA Voutsadakis, CN Papandreou Breast cáncer: basic and clinical research 3, 117822340900300001, 2009 | 54 | 2009 |
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer F Taza, AE Holler, W Fu, H Wang, N Adra, C Albany, R Ashkar, HH Cheng, ... JCO Precision Oncology 5, 1200-1220, 2021 | 50 | 2021 |
Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer PJ Vlachostergios, MJ Niaz, M Sun, SA Mosallaie, C Thomas, PJ Christos, ... Frontiers in oncology 11, 630589, 2021 | 47 | 2021 |
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner PJ Vlachostergios, E Hatzidaki, CD Befani, P Liakos, CN Papandreou Investigational new drugs 31, 1169-1181, 2013 | 43 | 2013 |
A broad-spectrum integrative design for cancer prevention and therapy KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35 (Suppl), S276, 2015 | 42 | 2015 |
The molecular limitations of biomarker research in bladder cancer PJ Vlachostergios, BM Faltas World journal of urology 37, 837-848, 2019 | 40 | 2019 |